Long term survival analysis of high dose versus low dose cis-platinum combined with cyclophosphamide in advanced ovarian cancer

A long-term survival analysis of a randomized study of high dose (HD) versu s low dose (LD) cis-platinum (DDP) combined with cyclophosphamide in advanc ed ovarian cancer conducted between 1983 and 1987 was performed. Kaplan-Mei er survival analysis showed that the dosage of DDP, size of residual tumour (RTS) (nil, <2cm and >2 cm) and site of residual tumour (nil, pelvis only, abdomen) were significant prognostic factors. Age, FIGO stage (3, 4 and rec urrence) and cell types were not significant. Multivariate Cox regression a nalysis showed that only RTS and DDP dosage were significant prognostic fac tors. The 10 year survival rates of patients receiving HD was 47.7% compare d to 14% in the LD group. High dose DDP has significant long term survival advantage over low dose DDP combined with cyclophosphamide. Size of residua l tumour remained one of the important prognostic factors independent of th e dosage of DDP.